News · 26 weeks62-38%
2026-03-012026-08-23
Mix3790d
- Insider23(62%)
- Other9(24%)
- SEC Filings4(11%)
- Analyst1(3%)
Latest news
25 items- INSIDERDirector Barchas Isaac sold $2,198,910 worth of shares (83,464 units at $26.35) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 92,211 units (SEC Form 4)4 - Immunome Inc. (0001472012) (Issuer)
- SECSEC Form S-8 filed by Immunome Inc.S-8 - Immunome Inc. (0001472012) (Filer)
- SECSEC Form 10-Q filed by Immunome Inc.10-Q - Immunome Inc. (0001472012) (Filer)
- SECImmunome Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Immunome Inc. (0001472012) (Filer)
- PRImmunome Reports Second Quarter 2026 Financial Results and Provides Business UpdateVaregacestat PDUFA target action date set for April 28, 2027, following U.S. FDA acceptance of New Drug Application (NDA) for adults with desmoid tumors Detailed Phase 3 RINGSIDE data presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, demonstrating statistically significant improvements across the primary and all key secondary endpoints First patient dosed in June 2026 in Phase 1 trial of IM-1617, a potential first-in-class solid tumor antibody-drug conjugate incorporating HC74, Immunome’s proprietary TOP1 inhibitor payload First patient dosed in July 2026 in Phase 1 trial of IM-3050, an investigational fibroblast activation prote
- INSIDERDirector Barchas Isaac sold $940,453 worth of shares (36,088 units at $26.06) as part of a pre-agreed trading plan (SEC Form 4)4 - Immunome Inc. (0001472012) (Issuer)
- INSIDERCHIEF BUSINESS OFFICER Horn Kinney exercised 90,616 shares at a strike of $11.89 and sold $2,273,555 worth of shares (90,616 units at $25.09) as part of a pre-agreed trading plan (SEC Form 4)4 - Immunome Inc. (0001472012) (Issuer)
- PRImmunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Immunome, Inc. (the "Company") (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on August 3, 2026, the Compensation Committee of the Company’s Board of Directors (the "Compensation Committee") granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 176,500 shares of common stock to nine new employees under the Company’s 2024 Inducement Plan. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to
- INSIDERChief Scientific Officer Higgins Jack was granted 38,250 shares, increasing direct ownership by 174% to 60,250 units (SEC Form 4)4 - Immunome Inc. (0001472012) (Issuer)
- INSIDERChief Technical Officer Tsai Philip was granted 38,250 shares, increasing direct ownership by 88% to 81,550 units (SEC Form 4)4 - Immunome Inc. (0001472012) (Issuer)
- INSIDERCHIEF LEGAL OFFICER & GC Stoneman Sandra G. was granted 38,250 shares, increasing direct ownership by 689% to 43,805 units (SEC Form 4)4 - Immunome Inc. (0001472012) (Issuer)
- INSIDERCHIEF BUSINESS OFFICER Horn Kinney was granted 31,250 shares (SEC Form 4)4 - Immunome Inc. (0001472012) (Issuer)
- INSIDERChief Financial Officer Rosett Max was granted 47,250 shares, increasing direct ownership by 87% to 101,287 units (SEC Form 4)4 - Immunome Inc. (0001472012) (Issuer)
- INSIDERPresident and CEO Siegall Clay B was granted 180,000 shares, increasing direct ownership by 26% to 870,704 units (SEC Form 4)4 - Immunome Inc. (0001472012) (Issuer)
- INSIDERChief Medical Officer Lechleider Robert was granted 54,000 shares, increasing direct ownership by 342% to 69,805 units (SEC Form 4)4 - Immunome Inc. (0001472012) (Issuer)
- PRImmunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid TumorsIM-3050 is a fibroblast activation protein (FAP)-targeted radioligand therapy designed to deliver radioactive lutetium-177 directly to FAP-expressing cells.The Phase 1 trial is designed to evaluate the safety, tolerability, dosimetry, pharmacokinetics, and preliminary anti-tumor activity of IM-3050 in participants with FAP-expressing advanced solid tumors.Immunome, Inc. (NASDAQ:IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that the first patient has been dosed in the Phase 1, first-in-human trial of IM-3050, an investigational FAP-targeted radioligand therapy being evaluated in patients with FAP-expressing a
- INSIDERCHIEF BUSINESS OFFICER Horn Kinney exercised 1,092 shares at a strike of $12.92 and sold $27,300 worth of shares (1,092 units at $25.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Immunome Inc. (0001472012) (Issuer)
- PRImmunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid TumorsPDUFA target action date set for April 28, 2027 Varegacestat could provide a meaningful new oral treatment option for adults with desmoid tumors if approved Immunome, Inc. (NASDAQ:IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the U.S. Food and Drug Administration (FDA or the Agency) has accepted its New Drug Application (NDA) for varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), for the treatment of adults with desmoid tumors. The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date of April 28, 2027. "The FDA’s acceptance of our NDA for varegac
- INSIDERDirector Barchas Isaac sold $2,412,522 worth of shares (100,000 units at $24.13) as part of a pre-agreed trading plan (SEC Form 4)4 - Immunome Inc. (0001472012) (Issuer)
- INSIDERChief Medical Officer Lechleider Robert exercised 55,000 shares at a strike of $8.73 and sold $1,244,331 worth of shares (55,000 units at $22.62) as part of a pre-agreed trading plan (SEC Form 4)4 - Immunome Inc. (0001472012) (Issuer)
- PRImmunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Immunome, Inc. (the "Company") (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on July 1, 2026, the Compensation Committee of the Company’s Board of Directors (the "Compensation Committee") granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 344,000 shares of common stock to seventeen new employees under the Company’s 2024 Inducement Plan. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal
- INSIDERDirector Barchas Isaac sold $4,393,024 worth of shares (201,050 units at $21.85) as part of a pre-agreed trading plan (SEC Form 4)4 - Immunome Inc. (0001472012) (Issuer)
- INSIDERChief Medical Officer Lechleider Robert exercised 55,000 shares at a strike of $8.73 and sold $1,091,662 worth of shares (55,000 units at $19.85) as part of a pre-agreed trading plan (SEC Form 4)4 - Immunome Inc. (0001472012) (Issuer)
- INSIDERChief Financial Officer Rosett Max sold $1,093,800 worth of shares (60,000 units at $18.23) as part of a pre-agreed trading plan and exercised 60,000 shares at a strike of $1.05 (SEC Form 4)4 - Immunome Inc. (0001472012) (Issuer)
- INSIDERSEC Form 4 filed by Director Swain Sandra M4 - Immunome Inc. (0001472012) (Issuer)
IMNM FAQ
7 questionsWhat does Immunome Inc. do?
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.Where does IMNM stock trade?
Immunome Inc. (IMNM) is listed on NASDAQ.What sector and industry is IMNM in?
Immunome Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Immunome Inc. go public?
Immunome Inc. (IMNM) completed its IPO in 2020.What are analysts saying about IMNM?
Immunome Inc. has had 8 recent analyst actions on file. The most recent action was from Barclays: Overweight with a $3600.00 price target on 2026-05-28. Recent price targets range from $2300.00 to $4000.00.What companies are similar to IMNM?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare IMNM side-by-side with any of them on Quantisnow.How can I track IMNM on Quantisnow?
Quantisnow aggregates Immunome Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IMNM to receive live email and push alerts on every new disclosure.